{
  "doc_id": "HTA_submission_sotosorib_FR",
  "chunks": [
    {
      "text": "Notice in favour of reimbursement as monotherapy in the treatment of adult patients with advanced non-small cell lung cancer (NCBC) with the KRAS G12C mutation, whose disease has progressed after at least one previous systemic treatment line. The continuation of this opinion is conditional on the re-evaluation of this specialty within a maximum of one year on the basis of the results of the Phase III study performed in patients with a CNBC with previously treated KRAS G12C mutation (CodeBreak 200).",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "Essentials",
        "start_page": 1,
        "end_page": 1,
        "split_index": 0
      }
    },
    {
      "text": "No progress in the management of adult patients with advanced non-small cell lung cancer with the KRAS G12C mutation, whose disease progressed after at least one previous systemic treatment line.",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "What progress has been made?",
        "start_page": 1,
        "end_page": 1,
        "split_index": 0
      }
    },
    {
      "text": "The systematic research of the KRAS mutation is recommended before starting the 1st treatment line of the CBNPC. The pronostic or predictive value of the KRAS G12C mutation is currently poorly defined in the CBNPC, and there is no (before the provision of LUMYKRAS (sotorasib)) specific treatment targeting this mutation. The current therapeutic management of the CBNPC is identical whether or not patients have a KRAS mutation (including G12C)",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "What is the place in the therapeutic strategy?",
        "start_page": 2,
        "end_page": 3,
        "split_index": 0
      }
    },
    {
      "text": ". At the metastatic stage (IV), it is recommended to propose a systematic second-line treatment, whether or not patients have responded to a 1st metastatic line. The nature of this treatment depends on the molecules used previously, on the ECOG score and on histology: - Patients treated with immunotherapy in a 1st treatment line, whether or not patients are treated with immunotherapy in a 1st treatment line, whether or not patients have responded to a 1st treatment line, whether or not patients have responded to a 1st treatment line.",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "What is the place in the therapeutic strategy?",
        "start_page": 2,
        "end_page": 3,
        "split_index": 1
      }
    },
    {
      "text": "Given the prognostic and predictive value currently poorly defined of the KRAS G12C mutation in CBNPC, and the absence of comparative data of acceptable methodological quality, the place of LUMYKRAS (sotorasib) vis-à-vis the available therapeutic alternatives (chemotherapy, immunotherapy) cannot be specified",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "What is the place in the therapeutic strategy?",
        "start_page": 2,
        "end_page": 3,
        "split_index": 2
      }
    },
    {
      "text": ". It should be noted that, in this context, no comparative data of acceptable methodological quality is available to guarantee the strength of the conclusion on the effect of the treatment with LUMYKRAS (sotorasib), the introduction of this drug into the therapeutic strategy accompanied by a greater risk-taking than for medicinal products whose efficacy is based on a comparison with an appropriate methodology",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "What is the place in the therapeutic strategy?",
        "start_page": 2,
        "end_page": 3,
        "split_index": 3
      }
    },
    {
      "text": ". Reason for review Registration In monotherapy in the treatment of adult patients with advanced non-small cell bronchial disease (CBNPC) cancer, presenting the relevant KRAS mutation G12C, whose disease has progressed after at least one previous systemic treatment line FAIBLE The maintenance of this notice is conditioned by a bona fide KRTS-prog-prog-prog-prog-prog-prog-g-prog-prog-g-g-prog-prog-g-prog-prog-prog-prog-prog-prog-prog-prog-prog-prog-prog-prog-prog-prog-prog-prog-prog-prog-prog-prog-prog-prog-prog-prog- forg-g-prog-g-g-g-g- forg- forg-g-g-g-g-g-g-g-g-g-g-g-g- forg-g-",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "What is the place in the therapeutic strategy?",
        "start_page": 2,
        "end_page": 3,
        "split_index": 4
      }
    },
    {
      "text": "forg-g-prog-g-g-g-g- forg- forg-g-g-g-g-g-g-g-g-g-g-g-g- forg-g- forg-g-g-g-g- forg-g-g-g-g-g-g-g-g-g-g-g-g-g-g-g-g-g-g-g-g-g-g-g-g-g-g-g-g-g- forg-g-g-g-g-g-g-g-g-g-g-g-g-g-g-g-g-g-g- forg-g-g-g-g-g-g-g-",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "What is the place in the therapeutic strategy?",
        "start_page": 2,
        "end_page": 3,
        "split_index": 5
      }
    },
    {
      "text": "For this purpose, the Commission considers that the disease has progressed after at least one previous systemic treatment line. LUMYKRAS (sotorasib) is not likely to have an additional impact on public health. Despite the low level of evidence of the data, and pending new data on efficacy and safety, the Commission considers that the disease has progressed after at least one previous systemic treatment line. LUMYKRAS (sotorasib) is not likely to have an additional impact on public health.",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "ASMR",
        "start_page": 3,
        "end_page": 3,
        "split_index": 0
      }
    },
    {
      "text": "This is an application for the inclusion of LUMYKRAS (sotorasib) on the list of specialities reimbursable to social policyholders and on the list of specialities approved for use by communities in the indication \"in monotherapy in the treatment of adult patients with advanced non-small cell bronchial cancer (NCBC) with the KRAS G12C mutation, whose disease progressed after at least one previous systemic treatment line.\" LUMYKRAS (sotorasib) obtained a conditional marketing authorization (MA) in the indication above on January 06, 2022",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "01 CONTEXT",
        "start_page": 4,
        "end_page": 4,
        "split_index": 0
      }
    },
    {
      "text": ". LUMYKRAS (sotorasib) has been the subject of a nominal ATU since December 01, 2020, and a cohort ATU since June 24, 2021 in a more restricted indication than the current application, as limited to metastatic stages only.",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "01 CONTEXT",
        "start_page": 4,
        "end_page": 4,
        "split_index": 1
      }
    },
    {
      "text": "\"LUMYKRAS is indicated as monotherapy in the treatment of adult patients with advanced non-small cell lung cancer (NCBC) with the KRAS G12C mutation, whose disease progressed after at least one previous systemic treatment line\"",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "02 I NDICATION",
        "start_page": 4,
        "end_page": 4,
        "split_index": 0
      }
    },
    {
      "text": "\" 4.2 Posology and method of administration Treatment with LUMYKRAS should be initiated by a physician experienced in the use of anticancer drugs. The presence of a KRAS G12C mutation should be confirmed with a validated test method before initiating treatment with LUMYKRAS. Posology The recommended dose is 960 mg of sotorasib (eight tablets of 120 mg) once daily, at the same time each day. Duration of treatment It is recommended to continue treatment with LUMYKRAS until the disease progresses or the appearance of unacceptable toxicity",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "03 P OSOLOGY",
        "start_page": 4,
        "end_page": 6,
        "split_index": 0
      }
    },
    {
      "text": ". Absence of dose or vomiting If less than 6 hours have passed since the expected time of dosing, the patient must take the forgotten dose as at the same time as at the same time. Duration of treatment It is recommended to continue treatment with LUMYKRAS until the disease progresses or the appearance of unacceptable toxicity. Absence of dose or vomiting If less than 6 hours have elapsed since the expected time of dosing, the patient must take the forgotten dose as at the same time as at the usual time of pregnancy",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "03 P OSOLOGY",
        "start_page": 4,
        "end_page": 6,
        "split_index": 1
      }
    },
    {
      "text": ". Absence of the non-deadverted cancers in the non-deadverted cancers in the non-abs in the second-abs in the second-abs in the second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second-",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "03 P OSOLOGY",
        "start_page": 4,
        "end_page": 6,
        "split_index": 2
      }
    },
    {
      "text": "second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second- second-",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "03 P OSOLOGY",
        "start_page": 4,
        "end_page": 6,
        "split_index": 3
      }
    },
    {
      "text": "The French recommendations recommend that molecular alterations (including the KRAS mutation) be investigated before starting the 1st treatment line 3 . 4 The prevalence of the KRAS G12C mutation in CBNPC has been estimated at approximately 14% . The prognostic or predictive value of the KRAS G12C mutation is currently poorly defined in CBNPC 5 , 6 , and there is no (before the provision of LUMYKRAS (sotorasib)) specific treatment targeting this mutation. The current therapeutic management of CBNPC is identical, whether or not patients have a KRAS mutation (including G12C)",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "03 P OSOLOGY",
        "start_page": 4,
        "end_page": 6,
        "split_index": 4
      }
    },
    {
      "text": ". The management of patients with advanced CBNPC, whose disease has progressed after at least one prior mutation mutation is based on a systemic mutation. At the metastatic stage (IV), it is recommended to propose a treatment of second-line systematically, whether or not patients have responded to a 1-line metastatic mutation. The nature of 2 this treatment depends on the molecules used previously, on the metamorphosis of the CBNORS, on which the metastatic mutation is not used",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "03 P OSOLOGY",
        "start_page": 4,
        "end_page": 6,
        "split_index": 5
      }
    },
    {
      "text": ". At the metastatic mutation (IV), it is recommended to propose a treatment of a second-line treatment, whether patients have responded or not a metastatic.",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "03 P OSOLOGY",
        "start_page": 4,
        "end_page": 6,
        "split_index": 6
      }
    },
    {
      "text": "(vinorelbine) Pierre Fabre and No CBNPC NA - NA - NA - Yes generics: Accord, Arrow, Sandoz",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "05.1 Medicinal products",
        "start_page": 7,
        "end_page": 7,
        "split_index": 0
      }
    },
    {
      "text": "(paclitaxel) BMS and In combination with cisplatin, generics: in CBNPC for which Accord, Arrow, a potentially non-NA surgery 的 NA 的 Yes Celgene, EG, curative and/or Hospira, Kabi, radiotherapy is not Mylan, indicated Ratiopharm, Teva, Sandoz TAXOTERE In combination with cisplatin, 21/07/2004 Important ASMR IV (minor) in relation to the combination of vinorelbine- Yes (docetaxel) in CBNPC not (inscription) cisplatin Sanofi and resectable, locally generic: advanced or metastatic, No Accord, Amring, in patients not having Arrow, Ebewe, received chemotherapy EG, Hospira, anterior Kabi, Pfizer",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "TAXOL",
        "start_page": 7,
        "end_page": 8,
        "split_index": 0
      }
    },
    {
      "text": "in patients not having Arrow, Ebewe, received chemotherapy EG, Hospira, anterior Kabi, Pfizer ALIMTA Second-level monotherapy 25/05/2016 Important ASMR V in management Yes No (pemetrexed) line of CBNPC, dis upon (reassessment) Lilly, Pfizer ALIMTA Second-level monotherapy No",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "TAXOL",
        "start_page": 7,
        "end_page": 8,
        "split_index": 1
      }
    },
    {
      "text": ".",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "TAXOL",
        "start_page": 7,
        "end_page": 8,
        "split_index": 2
      }
    },
    {
      "text": "or metastatic after an exception (atezolizumab) No previous chemotherapy of Roche patients ALK+) Squad CBNPC 03/02/2016 Important ASMR III (moderate) compared to docetaxel Yes locally advanced or (registration) metastatic after previous chemotherapy OPDIVO (nivolumab) No non-squad CBNPC 11/01/2017 Important ASMR IV (mine) compared to locally advanced BMS docetaxel or (registration) (only metastatic after previous chemotherapy patients ECOG 0 or 1) CBNPC locally advances 03/03/2021 Important ASMR IV (minor) compared to docetaxel Yes or metastatic, with PD-L1 (reassessment) (reassessment)",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "TECENTRIQ",
        "start_page": 8,
        "end_page": 8,
        "split_index": 0
      }
    },
    {
      "text": "≥ 1%, and having received at least the exception (pembrolizumab) Not chemotherapy of previous MSD patients ALK+) * *pharmaceutical-therapeutic class; registered before the decree of 1999 governing MRS and ASMR ème GEMZAR (gemcitabine) and AVASTIN (bevacizumab) specialties are used off-MAH in 2 line and more and recommended (AURA recommendation); they are retained as clinically relevant comparators.",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "KEYTRUDA",
        "start_page": 8,
        "end_page": 8,
        "split_index": 0
      }
    },
    {
      "text": "Support care.",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "05.2 Non-medicinal comparators",
        "start_page": 9,
        "end_page": 9,
        "split_index": 0
      }
    },
    {
      "text": "The clinically relevant comparators of LUMYKRAS (sotorasib) in the indication of the evaluated MAH are the medicinal products listed in the table above, as well as the specialisations GEMZAR (gemcitabine) and AVASTIN (bevacizumab), in the context of non-MAH use for the latter two.",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "Conclusion",
        "start_page": 9,
        "end_page": 9,
        "split_index": 0
      }
    },
    {
      "text": "AMM in the United States The LUMYKRAS (sotorasib) specialty has an AMM in the United States with a superimposed wording \"treatment of adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, which have received at least one prior system therapy\". 的 Management Based on information provided by the laboratory: PRISE IN CHARGE Country Yes / No / Ongoing Population(s) AMM or Restricted Germany Yes MAMM population No (start of procedure Belgium N.A. after AMM) Spain Ongoing N.A. Italy Ongoing N.A",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "INTERNATIONAL",
        "start_page": 9,
        "end_page": 9,
        "split_index": 0
      }
    },
    {
      "text": ".A. after AMM) Spain Ongoing N.A. Italy Ongoing N.A. Netherlands Ongoing N.A. MAMM population in the United Kingdom \"LUMYKRAS is identified as monotherapy for the treatment of adult patients with KRAS G12C-progressed immuno-determinant N.A. Italy Current N.A. Netherlands Ongoing N.A. Population in the United Kingdom \"LUMYKRAS is identified with the treatment of adult patients with KRAS G12C-dether immuno-mated locally advanced N.",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "INTERNATIONAL",
        "start_page": 9,
        "end_page": 9,
        "split_index": 1
      }
    },
    {
      "text": "The application for the registration of LUMYKRAS (sotorasib) is based on: - a non-comparative phase I/II \"basket\" (CodeBreak 100) study whose main objective was to estimate the objective response rate (objective response rate) in various advanced solid tumours with the previously treated KRAS G12C mutation; only the part corresponding to the cohort of CBNPC patients in Phase II will be described in this opinion; - indirect comparisons between patients treated with LUMYKRAS (sotorasib) in the CodeBreak 100 study and those treated with other alternatives in the ESME cohort; - the first quarterly",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "07 A NALYSIS OF AVAILABLE DATA",
        "start_page": 10,
        "end_page": 10,
        "split_index": 0
      }
    },
    {
      "text": "100 study and those treated with other alternatives in the ESME cohort; - the first quarterly synthesis report of the cohort ATU",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "07 A NALYSIS OF AVAILABLE DATA",
        "start_page": 10,
        "end_page": 10,
        "split_index": 1
      }
    },
    {
      "text": ".",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "07 A NALYSIS OF AVAILABLE DATA",
        "start_page": 10,
        "end_page": 10,
        "split_index": 2
      }
    },
    {
      "text": "A Phase 1/2, Open-label Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Reference Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation Clinicaltrials.gov Registration No",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "7.1.1 CodeBreak Study 100",
        "start_page": 10,
        "end_page": 10,
        "split_index": 0
      }
    },
    {
      "text": ".: NCT03600883 Primary objective to estimate the objective response rate, evaluated by an independent review committee, in adults with advanced solid tumour with mutation KRAS G12C Phase I/II \"Basket\" study, non-comparative Study Type of study er including the 1 patient Date of the 1 patient included: 13/08/2019 Date of the last patient included: 05/02/20 Date and duration of the data extraction for the main analysis: 05/09/20 I Study Study conducted in 59 centres in 11 countries (including 4 centres in France with an initial infection therapy or an anti-injection procedure) - age ≥ 18 years -",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "7.1.1 CodeBreak Study 100",
        "start_page": 10,
        "end_page": 10,
        "split_index": 1
      }
    },
    {
      "text": "in France with an initial infection therapy or an anti-injection procedure) - age ≥ 18 years - advanced tumour",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "7.1.1 CodeBreak Study 100",
        "start_page": 10,
        "end_page": 10,
        "split_index": 2
      }
    },
    {
      "text": "The safety follow-up takes place 30 (+7) days after the end of treatment. Long-term follow-up of overall survival is carried out every 12 weeks. Patients received LUMYKRAS (sotorasib) orally (tablets), 960 mg once daily. Treatment was continued until disease progression, Treatments studied decision to stop the patient, death, loss of sight, sponsor's decision, non-compliance, pregnancy, adverse event, intolerance, need for a therapeutic alternative. Objective response rate evaluated by an independent review committee according to Criterion of judgement the criteria RECIST 1",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "Study diagram",
        "start_page": 10,
        "end_page": 11,
        "split_index": 0
      }
    },
    {
      "text": ".1 and defined as the proportion of patients with a complete or partial primary response. This response was to be confirmed by a second imaging performed at least 4 weeks later.",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "Study diagram",
        "start_page": 10,
        "end_page": 11,
        "split_index": 1
      }
    },
    {
      "text": "- duration of response: delay between the 1st partial or complete response to the 1st relapse or progression (RECIST criteria 1",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "Study diagram",
        "start_page": 10,
        "end_page": 11,
        "split_index": 2
      }
    },
    {
      "text": ".1) or death any cause Key criteria - disease control rate: proportion of patients with a complete, partial or stable judgement response ≥ 5 secondary weeks - delay until response: delay between the start of treatment and the 1st partial or complete response - progression-free survival, evaluated by an independent review committee: delay between the start of treatment and progression or death any cause - overall survival: delay between the beginning of treatment and death any cause - quality of life: assessed by QLQ-C30, QLQ-LC13 and EQ-5D-5L - tolerance The following assumptions were used for",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "Study diagram",
        "start_page": 10,
        "end_page": 11,
        "split_index": 3
      }
    },
    {
      "text": "assessed by QLQ-C30, QLQ-LC13 and EQ-5D-5L - tolerance The following assumptions were used for the calculation: - objective response rate observed under ramucirumab+docetaxel: 23% 9 - objective response rate expected under sotorasib: 32% Sample size - 90% power and unilateral alpha risk of 2",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "Study diagram",
        "start_page": 10,
        "end_page": 11,
        "split_index": 4
      }
    },
    {
      "text": ".5% Under these assumptions, 105 patients with CBNPC were to be included.",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "Study diagram",
        "start_page": 10,
        "end_page": 11,
        "split_index": 5
      }
    },
    {
      "text": "Method of analysis of results Population of analysis Efficacy analyses were carried out in the so-called full analysis set population, corresponding to patients receiving at least one dose of sotorasib + with at least one initial injury that can be assessed according to the RECIST criteria 1.1. Tolerance analyses were carried out in the safety population, corresponding to patients receiving at least one dose of sotorasib. Main amendments to the protocol - 08 Mar",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "Study diagram",
        "start_page": 10,
        "end_page": 11,
        "split_index": 6
      }
    },
    {
      "text": ". Main amendments to the protocol - 08 Mar. 2021: addition of an additional 240 mg arm to evaluate the efficacy, safety and pharmacokinetics of this dose (results available at the end of 2022 – early 2023)",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "Study diagram",
        "start_page": 10,
        "end_page": 11,
        "split_index": 7
      }
    },
    {
      "text": "- Data from 01/12/20 and 15/03/2021: corresponding to follow-up data, exploratory No",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "Results:",
        "start_page": 11,
        "end_page": 13,
        "split_index": 0
      }
    },
    {
      "text": ". of previous lines, n (%) Type of previous treatment*, n (%) Chimotherapy 115 (91%) Immunotherapy 116 (92%) Targeted therapy 30 (22%) Stage of inclusion, n (%) III 5 (4%) IV 121 (96%) Histology, n (%) Epidermoid 1 (1%) Non-epidermoid 125 (99%) Type of previous treatment*, n (%) Chimotherapy 115 (91%) Immunotherapy 116 (92%) Targeted therapy 30 (24%) Stage of initiation, n (%) III 5 (4%) Indeterminate patient (absolute patient (absolute patient (absolute patient (absolute patient) (absolute patient) (absolute patient) (absolute patient) (absolute patient) (absolute patient) (absolute patient)",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "Results:",
        "start_page": 11,
        "end_page": 13,
        "split_index": 1
      }
    },
    {
      "text": "(absolute patient) (absolute patient) (absolute patient) (absolute patient) (absolute patient) (absolute patient) (absolute patient) (absolute patient) (absolute patient) (absolute patient) (absolute patient) (absolute patient) (absolute patient) (absolute patient (absolute patient) (absolute patient) (absolvent patient) (absolvent patient (absolvent patient) (absolvent patient) (absolvent patient) (absolvent patient) (absolvent patient) (absolc patient (ab patient) (absolc patient) (absolc patient (ab patient) (ab) (ab) (ab) (ab) (ab) (ab) (absolb) (absolc) (absolc) (absolc) (absolc)",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "Results:",
        "start_page": 11,
        "end_page": 13,
        "split_index": 2
      }
    },
    {
      "text": "patient (ab patient) (ab) (ab) (ab) (ab) (ab) (ab) (absolb) (absolc) (absolc) (absolc) (absolc) (absolc) (absolc) (ab) (absolc) (absolc) (ab) (absolc) (ab) (ab) (ab) (ab) (ab) (ab) (ab) (absolc) (absolc) (ab) (ab) (ab) (ab) (ab) (absolc) (ab) (ab) (ab) (ab) (ab) (ab) (ab) (ab) (ab) (ab) (ab) (ab) (ab) (absolc) (ab) (absolc) (ab) (ab) (ab) (absolc)",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "Results:",
        "start_page": 11,
        "end_page": 13,
        "split_index": 3
      }
    },
    {
      "text": "In a very large majority of cases of partial response (44 patients, 34%), and in 4 cases (3%) of complete response, 43% of stable disease was noted. It should be noted that 20 patients (16%) had a progression of the disease. There is no data on the evolution of brain metastases. The data were similar to the exploratory follow-up analyses of December 01, 2020 and March 15, 2021, with the inclusion of an additional patient in the full-analysis set population, because they were finally considered to have at least one measurable initial lesion",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "Results:",
        "start_page": 11,
        "end_page": 13,
        "split_index": 4
      }
    },
    {
      "text": ". 的 Secondary Judgement Criteria The secondary, exploratory criteria are described in the table below (Table 2).",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "Results:",
        "start_page": 11,
        "end_page": 13,
        "split_index": 5
      }
    },
    {
      "text": "Data Freeze Data Freeze from 01/12/2020 01/09/2020 data N=124 15/03/2021 N=123 N=124 Follow-up, month Median (min-max) 9.3 (1.1-12.2) 12.2 (1.1-5.6) 15.3 (1.1-18.4) Duration of response, month Median [IC95%] 8.4 [6.9-8.4] 10.0 [6.9-11.1] 11.1 [6.9-NE] Rate of disease control, n(%) % [IC95%] 81% [72-87] 81% [73-87] 81% [73-87] Time to response, month Median (min-max) 1.4 (1.2-6.1) 1.4 (1.2-10.1) 1.4 (1.2-10.1) Survival without progression, month Median [IC95%] 6.7 [4.9-8.1] 6.8 [5.1-8.2] 6.8 [5.1-8.2] Overall Survival, month Median [IC95%] 12.0 [9.5-NE] 12.5 [10.0-NE] 12.5 [10.0-NE]",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "Table 2. Exploratory Secondary Judgement Criteria for the CodeBreak Study 100",
        "start_page": 13,
        "end_page": 13,
        "split_index": 0
      }
    },
    {
      "text": "An indirect comparison was made between patients in the CodeBreak 100 study treated with sotorasib, and patients in the ESME cohort treated with standard treatments. Individual data were available for the CodeBreak 100 study. For the ESME cohort, only aggregated data were available. This was in both cases of non-comparative studies. The methodology used was of the unanchored MAIC type (matching adjusted indirect comparison).",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "7.1.2 Indirect comparison data",
        "start_page": 13,
        "end_page": 13,
        "split_index": 0
      }
    },
    {
      "text": "- the absence of residual confusion, a hypothesis necessary for this type of method, cannot be assured: o the analysis of princeps n, having held that 3 prognostic variables, whereas other confounding factors had been listed a priori; o the consideration of the 11 confounding factors measured, in another analysis, effective sample size leads to an effective size of small sample not allowing an accurate or even valid estimate of the effect of treatment; o there appear to be unmeasured confounding factors (albuminemia, hepatic function, renal function, LDH, delay since the last treatment line):",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "This indirect comparison, however, has methodological limitations.",
        "start_page": 13,
        "end_page": 14,
        "split_index": 0
      }
    },
    {
      "text": "factors (albuminemia, hepatic function, renal function, LDH, delay since the last treatment line): these potential confounding factors not being recorded (or missing too large data) in the ESME cohort; o patients with active brain metastases (excluding from the study CodeBreak 100, at a more unfavourable prognosis) were not excluded from the ESME cohort (information on the activity of non-available metastases); o patients with active cerebral metastases; o patients with missing metastases (excluded from the study CodeBreak 100, at a more unfavourable prognosis) were not excluded from the ESME",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "This indirect comparison, however, has methodological limitations.",
        "start_page": 13,
        "end_page": 14,
        "split_index": 1
      }
    },
    {
      "text": "from the study CodeBreak 100, at a more unfavourable prognosis) were not excluded from the ESME cohort (information on metastasis activity information on metastasis activity information; - the imprecognition data; - not considered to be considered to be a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "This indirect comparison, however, has methodological limitations.",
        "start_page": 13,
        "end_page": 14,
        "split_index": 2
      }
    },
    {
      "text": "a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a not a",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "This indirect comparison, however, has methodological limitations.",
        "start_page": 13,
        "end_page": 14,
        "split_index": 3
      }
    },
    {
      "text": "The quality of life of patients was analysed in the CodeBreak 100 study in exploratory analyses using 2 questionnaires: QLQ-C30, QLQ-LC13 and EQ-5D-5L. However, this assessment includes several limitations: - it is not comparative, not allowing to estimate the proper effect of sotorasib treatment on the quality of life; - no objective was pre-specified in the protocol for the clinical relevance of the results, in particular the significant minimum clinically relevant differences in the population of interest were not discussed a priori",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "07.2 Quality of life",
        "start_page": 14,
        "end_page": 14,
        "split_index": 0
      }
    },
    {
      "text": ". Overall, given these reservations, no formal conclusions can be drawn on the quality of life, the results of which will not be presented.",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "07.2 Quality of life",
        "start_page": 14,
        "end_page": 14,
        "split_index": 1
      }
    },
    {
      "text": "The safety data described are those from the base gel of March 15, 2021, allowing the greatest decline. The tolerability population was 126 patients. As of March 15, 2021, the median duration of treatment with sotorasib was 24 weeks (min-max: 1-77). Almost all patients reported an adverse event (EI) (99%). The proportion of AEs of grades ≥ 3 was 61%. The proportion of serious AEs was 55%. The proportion of AEs leading to discontinuation of treatment with sotorasib was 9%. The proportion of AEs evolving towards death was 16%. The most frequent AEs are detailed in the table below. Table 3",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "7.3.1 Data from the CodeBreak study 100",
        "start_page": 14,
        "end_page": 14,
        "split_index": 0
      }
    },
    {
      "text": ". The most frequent AEs are detailed in the table below. Table 3. The most common adverse events in the study CodeBreak 100 AEs of all grade grades ≥ 3 Diarrheas 64 (51%) 7 (6%) Nausea 39 (31%) 1 (1%) Fatigue 32 (25%) 3 (2%) Arthralgia 27 (21%) was 3 (2%) were reported to be 3 (2%) had an AE of all grade grades 24% (21%) had an AST of 29% had an AST of 97% (6%) had an AST of 29% had an AST of 29% had an AE of 29% had an A.",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "7.3.1 Data from the CodeBreak study 100",
        "start_page": 14,
        "end_page": 14,
        "split_index": 1
      }
    },
    {
      "text": "The risk summary of the LUMYKRAS (sotorasib) RMP (version 0.3 of September 28, 2021) is presented in the table below: Significant Risks Identified - No Potential Significant Risks - No Missing Information - Use in patients with hepatic impairment",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "7.3.2 Risk Management Plan (RMP) Data",
        "start_page": 15,
        "end_page": 15,
        "split_index": 0
      }
    },
    {
      "text": "The PBRER/PSUR (Periodic Benefit-Risk Evaluation Report/Periodic Safety Update Report ) covering the period from 21 May 2021 to 27 November 2021 was provided. During this period, a signal on interstitial pneumonitis was analysed and considered to be a significant risk identified.",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "Data from PSURs",
        "start_page": 15,
        "end_page": 15,
        "split_index": 0
      }
    },
    {
      "text": "\"4.4 Special warnings and precautions for use Hepatotoxicity Sotorasib may cause hepatotoxicity, which may result in hepatic lesions of drug origin or hepatitis. Sotorasib has been associated with transient elevations in serum transaminase levels (ALT and ASAT). These elevations have been reduced or resolved by dose adjustment or definitive discontinuation of treatment and have resulted in no hepatic impairment or death in clinical studies. Among patients with hepatotoxicity, 38% had hepatotoxicity that resulted in discontinuation of treatment or dose reduction",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "Data from SPC",
        "start_page": 15,
        "end_page": 15,
        "split_index": 0
      }
    },
    {
      "text": ". Overall, 26% of patients with hepatotoxicity received concomitantly-absorbed corticosteroids.",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "Data from SPC",
        "start_page": 15,
        "end_page": 15,
        "split_index": 1
      }
    },
    {
      "text": "Treatment should be permanently discontinued if no other potential cause of PI/inflammatory pneumopathy is identified (see section 4.2).'",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "Data from SPC",
        "start_page": 15,
        "end_page": 15,
        "split_index": 2
      }
    },
    {
      "text": "The laboratory provided the results of the first quarterly synthesis report of the cohort ATU, covering the period from August 09, 2021 to October 29, 2021. As a reminder, the wording of this cohort ATU was: \"Sotorasib is indicated as monotherapy in the treatment of adult patients with non-small cell bronchial cancer (NCBC) KRAS p.G12C metastatic mutated, pre-treated.\" A total of 447 requests for access to treatment were made during this period, 7 of which were denied. Of the 440 accepted applications, 414 patients were considered treated (laboratory-provided medicine)",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "07.4 Usage data",
        "start_page": 15,
        "end_page": 16,
        "split_index": 0
      }
    },
    {
      "text": ". Of these, 403 patients were considered to be exposed to sotorasib (11 patients who had never initiated treatment). The 414 patients considered to have been treated were described as prior to this period, 7 of which were denied. The median age was 66 years (min-max: 36-88), and the majority of the patients were men (57%). It was essentially a former smokers (82%) or active smokers (14%). The insufficiently-treated patients (i.e.09), the meta-de.g.d.d.d",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "07.4 Usage data",
        "start_page": 15,
        "end_page": 16,
        "split_index": 1
      }
    },
    {
      "text": ". The insufficiently-treated patients (i.e.09), the meta-de.g.d.d.d. was not-yyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyy",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "07.4 Usage data",
        "start_page": 15,
        "end_page": 16,
        "split_index": 2
      }
    },
    {
      "text": "The request for the inclusion of LUMYKRAS (sotorasib) in the monotherapy indication in the treatment of adult patients with advanced NSCLC with the KRAS G12C mutation, whose disease progressed after at least one previous systemic treatment line, is based primarily on a non-comparative Phase 2 \"basket\" study (CodeBreak 100) and indirect comparison data. The CodeBreak 100 study is a \"basket\" study that included adult patients with advanced solid tumours with the KRAS G12C mutation",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "07.5 Summary & Discussion",
        "start_page": 16,
        "end_page": 18,
        "split_index": 0
      }
    },
    {
      "text": ". The primary judgement criterion for the cohort of patients with NSCLC was the objective response rate , evaluated by an independent review committee, according to the RECIST criteria. 1.1. Only the data from the cohort CBNPC were used for this evaluation.",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "07.5 Summary & Discussion",
        "start_page": 16,
        "end_page": 18,
        "split_index": 1
      }
    },
    {
      "text": "Among the secondary endpoints, the median duration of response was 8.4 months (IC95%: 6.9-8.4), progression-free survival of 6.7 months (IC95%: 4.9-8.1) and overall survival of 12.0 months (9.5-NE). Follow-up exploratory data suggested similar results. However, an indirect comparison was performed using patients included in the CodeBreak study, and those treated by standard treatment in the ESME cohort, using a non-anchored MAIC (matching adjusted indirect comparison ) method",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "07.5 Summary & Discussion",
        "start_page": 16,
        "end_page": 18,
        "split_index": 2
      }
    },
    {
      "text": ". However, the main underlying hypothesis of this type of group comparability adjustment method, namely the exhaustive consideration of the confounding factors, is not verified. Indeed, a very small number of these factors could be introduced into the main adjustment model, either by lack of collection of these factors, or to maintain a sufficient sample size effective in the sotorasib group. Finally, for one of these factors (ECOG score), 62% of missing data were also missing from the laboratory data, thus missing from the laboratory data.",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "07.5 Summary & Discussion",
        "start_page": 16,
        "end_page": 18,
        "split_index": 3
      }
    },
    {
      "text": "In view of the non-comparative design of the study, no formal conclusions can be drawn on the quality of life. 的 Tolerance The safety data of the CodeBreak 100 study are derived from the data freeze of March 15, 2021, allowing the largest decline. The safety population was 126 patients, with a median duration of treatment of 24 weeks (min-max: 1-77). Almost all patients reported an adverse event (AE) (99%). The proportion of IEs of grades ≥ 3 was 61%, that of serious IEs of 55%, that of IEs leading to discontinuation of treatment of 9%, and that of IEs evolving towards death of 16%",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "07.5 Summary & Discussion",
        "start_page": 16,
        "end_page": 18,
        "split_index": 4
      }
    },
    {
      "text": ". The events of special interest were reported in 39% of patients. The occurrences of special interest were reported in the number of patients.",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "07.5 Summary & Discussion",
        "start_page": 16,
        "end_page": 18,
        "split_index": 5
      }
    },
    {
      "text": "This study revealed an objective response rate, evaluated by an independent committee of 37% [IC95%: 29-47]",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "07.5 Summary & Discussion",
        "start_page": 16,
        "end_page": 18,
        "split_index": 6
      }
    },
    {
      "text": ". However, it should be noted that: - the non-compromising design allows only an estimate of the absolute effect of LUMYKRAS (sotorasib), and not its additional relative efficacy in relation to the efficacy of existing treatments, the placebo effect and the natural evolution of the disease; - this result was observed in a selected population (notably with ECOG 0 or 1, the absence of active brain metastasis): the transposability of the results to a population of worse prognosis (ECOG > 1, active brain metastasis) cannot be assured; and the safety profile was marked by an incidence of adverse",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "07.5 Summary & Discussion",
        "start_page": 16,
        "end_page": 18,
        "split_index": 7
      }
    },
    {
      "text": "brain metastasis) cannot be assured; and the safety profile was marked by an incidence of adverse events of grade ≥ 3 in nearly two of three patients (61%) and that of serious adverse events in more than two patients (55%), taking into account efficacy and safety data (preliminary data in a non-comparative study while clinically relevant comparators were available), additional bounds, estimated morbidity in terms of data (b",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "07.5 Summary & Discussion",
        "start_page": 16,
        "end_page": 18,
        "split_index": 8
      }
    },
    {
      "text": ".09b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.d.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b.b",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "07.5 Summary & Discussion",
        "start_page": 16,
        "end_page": 18,
        "split_index": 9
      }
    },
    {
      "text": "Availability Name of Study Diagram Data Phase III randomised, open-label versus docetaxel, in CodeBreak late 2022 - early adult patients with advanced CNSC with 200 2023 KRAS G12C mutation, previously treated IFCT-2012 Retrospective observational study including Lung Fin 2022 patients treated with ATUc KG12Ci",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "07.6 NSCLC Study Program",
        "start_page": 18,
        "end_page": 18,
        "split_index": 0
      }
    },
    {
      "text": "The systematic research of the KRAS mutation is recommended before starting the 1st treatment line of the CBNPC. The pronostic or predictive value of the KRAS G12C mutation is currently poorly defined in the CBNPC, and there is no (before the provision of LUMYKRAS (sotorasib)) specific treatment targeting this mutation. The current therapeutic management of the CBNPC is identical whether or not patients have a KRAS mutation (including G12C)",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "08 P LAKE IN THE THERAPEUTIC STRATEGY",
        "start_page": 18,
        "end_page": 19,
        "split_index": 0
      }
    },
    {
      "text": ". At the metastatic stage (IV), it is recommended to propose a treatment of second-line systematically, whether or not patients have responded to a 1-line metastatic. The nature of this treatment depends on the molecules used previously, the ECOG score and the histology: - Patients treated by immunotherapy in low-level cells. At the metastatic stage (IV), it is recommended to propose a treatment of second-line systematically, whether or not patients have responded to a 1-line metastatic line.",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "08 P LAKE IN THE THERAPEUTIC STRATEGY",
        "start_page": 18,
        "end_page": 19,
        "split_index": 1
      }
    },
    {
      "text": "In view of the currently poorly defined prognostic and predictive value of the KRAS G12C mutation in CBNPC, and the lack of comparative data of acceptable methodological quality, the place of LUMYKRAS (sotorasib) vis-à-vis the available therapeutic alternatives (chemotherapy, immunotherapy) cannot be specified",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "08 P LAKE IN THE THERAPEUTIC STRATEGY",
        "start_page": 18,
        "end_page": 19,
        "split_index": 2
      }
    },
    {
      "text": ". It should be noted that, in this context, where no comparable data of acceptable methodological quality is available to ensure the strength of the conclusion on the effect of treatment with LUMYKRAS (sotorasib), the introduction of this drug into the therapeutic strategy is accompanied by a greater risk-taking than for medicinal products whose efficacy is based on a comparison with an appropriate methodology. The Summary of Product Characteristics (SPC) and the Risk Management Plan (RMP) must be respected.",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "08 P LAKE IN THE THERAPEUTIC STRATEGY",
        "start_page": 18,
        "end_page": 19,
        "split_index": 3
      }
    },
    {
      "text": "Considering all this information and after debate and vote, the Commission considers that:",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "09 C C ONCLUSIONS OF THE OMMISSION",
        "start_page": 19,
        "end_page": 19,
        "split_index": 0
      }
    },
    {
      "text": "The LUMYKRAS (sotorasib) speciality is a curative drug. It is poorly established as a result of: - lack of robust comparison data when clinically relevant comparators were available; - weak demonstration of efficacy: preliminary data from a non-comparative Phase I/II study; - frequent and serious adverse reactions (including hepatotoxicity and nephrotoxicity)",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "09.1 Medical Service",
        "start_page": 19,
        "end_page": 19,
        "split_index": 0
      }
    },
    {
      "text": ". 的 There are non-specific therapeutic alternatives to the KRAS G12C mutation, in a context where the prognostic and predictive value of this mutation is poorly defined and the lack of specific treatment (before the provision of LUMYKRAS (sotorasib)) is an option for treatment in patients who have received at least one previous systemic treatment line.",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "09.1 Medical Service",
        "start_page": 19,
        "end_page": 19,
        "split_index": 1
      }
    },
    {
      "text": "Given: - the severity of the disease, - the partially covered medical need, - the lack of any additional response to the identified need, in the absence of demonstrated impact on morbi-mortality and quality of life, - the lack of data to assess any additional impact on the care and/or life course. LUMYKRAS (sotorasib) is not likely to have an additional impact on public health. Considering all of these elements, the Commission considers that the medical service rendered by LUMYKRAS (sotorasib) is low in the indication of the MAH",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "Public health interest",
        "start_page": 19,
        "end_page": 20,
        "split_index": 0
      }
    },
    {
      "text": ". The Commission gives a favourable opinion on the inclusion on the list of reimbursable specialties for social policy holders and on the list of authorised specialities for use by communities in the indication of the MAH and at the dosages of the MAH. The Commission conditions the continued low MRL to the re-evaluation of this specialty within a maximum of one year on the basis of the results of the proposed Phase III study for patients with a KBPC, which is expected to be reimbursed for the KBPC, with a previously-treated K12 (KRKRK2:",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "Public health interest",
        "start_page": 19,
        "end_page": 20,
        "split_index": 1
      }
    },
    {
      "text": "- the poor quality of the demonstration of efficacy of LUMYKRAS (sotorasib), based on data from a non-comparative Phase I/II study; - the poorly defined prognostic and predictive value of the KRAS G12C mutation in CBNPC; - the uncertainty about the relative effectiveness of this treatment, considering the absence of direct comparison and the methodological weakness of the indirect comparison provided, in a context where direct comparison with a therapeutic alternative available with a robust methodology is possible, - the safety profile, marked by the incidence of serious adverse events (AEs)",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "Taking into account:",
        "start_page": 20,
        "end_page": 20,
        "split_index": 0
      }
    },
    {
      "text": "is possible, - the safety profile, marked by the incidence of serious adverse events (AEs) reported in more than half of patients (55%) and that of AIs ≥ 3 in nearly two thirds of patients (61%) the Transparency Commission considers that LUMYKRAS (sotorasib) does not provide improvement of the medical service rendered (ASMR V) in the management of adult patients with advanced CBPNC, with the KRAS G12C mutation, whose disease has progressed after at least one previous systemic treatment line",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "Taking into account:",
        "start_page": 20,
        "end_page": 20,
        "split_index": 1
      }
    },
    {
      "text": ".",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "Taking into account:",
        "start_page": 20,
        "end_page": 20,
        "split_index": 2
      }
    },
    {
      "text": "The target population of LUMYKRAS (sotorasib) is adult patients with advanced CBNPC cancer, with the KRAS G12C mutation, whose disease progressed after at least one previous systemic treatment line. In France, the number of new lung cancer cases was estimated in 2018 at 46,363. The 10 CBNPCs represent 85% of the histological types, or 39,409 patients. According to the KBP-2010-CHG study, approximately 80% of patients with CBNPC were diagnosed at an advanced or metastatic stage (stage III or IV), or 31,528 patients",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "09.3 Target population",
        "start_page": 20,
        "end_page": 20,
        "split_index": 0
      }
    },
    {
      "text": ". Furthermore, it is estimated that 40% of patients diagnosed at a localized stage will progress to an advanced stage or 11 metastatic stage in the year, or 3,153 additional patients. Thus, the number of patients with advanced or metastatic CBNPCs is estimated to be 34,681 patients. 3 The prevalence of the KRAS G12C mutation is estimated at 14%, or approximately 4,856 patients. Based on data from the ESME cohort (estimated to be an estimated 950-year ratio), approximately 40% of patients received with a KNPC mutation at approximately 912.",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "09.3 Target population",
        "start_page": 20,
        "end_page": 20,
        "split_index": 1
      }
    },
    {
      "text": "The Commission would like to receive the results of the ongoing Phase III study (CodeBreak 200) within a maximum period of one year, the results of which are expected by 31 March 2023.The Commission will reassess LUMYKRAS (sotorasib) in the light of these data and any new data available.",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "010 A R C USES OF THE COMMENDATIONS OF THE OMMISSION",
        "start_page": 20,
        "end_page": 21,
        "split_index": 0
      }
    },
    {
      "text": "Date of administrative validation*: 07/02/22 Calendar Date of examination: 20/04/2022 devaluation Date of adoption: 11/05/2022 Date of laboratory hearing: 15/06/2022 Stakeholders (including patient associations and Yes",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "011 I ADMINISTRATIVE AND REGULATORY INFORMATION",
        "start_page": 21,
        "end_page": 21,
        "split_index": 0
      }
    },
    {
      "text": "No Submissions LUMYKRAS 120 mg Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "External expertise",
        "start_page": 21,
        "end_page": 21,
        "split_index": 0
      }
    },
    {
      "text": "Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "External expertise",
        "start_page": 21,
        "end_page": 21,
        "split_index": 1
      }
    },
    {
      "text": "Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Ent Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Entries Ent",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "External expertise",
        "start_page": 21,
        "end_page": 21,
        "split_index": 2
      }
    },
    {
      "text": "Row 1:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <的 Which place in the therapeutic strategy?>",
        "start_page": 1,
        "end_page": 1,
        "split_index": 0
      }
    },
    {
      "text": "I'm sorry, but I don't know.",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <ASMR>",
        "start_page": 3,
        "end_page": 3,
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Reason for Examination & Registration: Row 2: Relevant Indications: In monotherapy in the treatment of adult patients with cancers: Row",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <ASMR>",
        "start_page": 3,
        "end_page": 3,
        "split_index": 1
      }
    },
    {
      "text": "Row 2: Relevant Indications: In monotherapy in the treatment of adult patients with cancers: Row 3:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <ASMR>",
        "start_page": 3,
        "end_page": 3,
        "split_index": 2
      }
    },
    {
      "text": "Row 1: Indication Row 2: concerned",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <ASMR>",
        "start_page": 3,
        "end_page": 3,
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Place in Row 2: Row 3: therapeutic strategy",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <ASMR>",
        "start_page": 3,
        "end_page": 3,
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NAME (INN) LaboratoryoCPT*",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <TAXOL>",
        "start_page": 7,
        "end_page": 7,
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NAME Row 2: (INN) Row 3: Laboratory",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <TAXOL>",
        "start_page": 7,
        "end_page": 7,
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Take Row 2: in Row 3: charge",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <TAXOL>",
        "start_page": 7,
        "end_page": 7,
        "split_index": 0
      }
    },
    {
      "text": "Row 1: SMR Row 2:",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <TAXOL>",
        "start_page": 7,
        "end_page": 7,
        "split_index": 0
      }
    },
    {
      "text": "Row 1: ASMR Row 2: (Lébellé)",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <TAXOL>",
        "start_page": 7,
        "end_page": 7,
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Lilly and generics: Kabi, Mylan, Ohre, Zentiva, and that histology is not predominantly epidermoid-like--------- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <KEYTRUDA>",
        "start_page": 8,
        "end_page": 8,
        "split_index": 0
      }
    },
    {
      "text": "-- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <KEYTRUDA>",
        "start_page": 8,
        "end_page": 8,
        "split_index": 1
      }
    },
    {
      "text": "-- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <KEYTRUDA>",
        "start_page": 8,
        "end_page": 8,
        "split_index": 2
      }
    },
    {
      "text": "Row 1: Countries--- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <INTERNATIONAL>",
        "start_page": 9,
        "end_page": 9,
        "split_index": 0
      }
    },
    {
      "text": "-- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <INTERNATIONAL>",
        "start_page": 9,
        "end_page": 9,
        "split_index": 1
      }
    },
    {
      "text": "-- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <INTERNATIONAL>",
        "start_page": 9,
        "end_page": 9,
        "split_index": 2
      }
    },
    {
      "text": "Row 1: Footnotes//////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <Schedule of the study>",
        "start_page": 10,
        "end_page": 10,
        "split_index": 0
      }
    },
    {
      "text": "Treatment was continued until disease progression, patient cessation decision, death, loss of sight, sponsor's decision, non-compliance, pregnancy, adverse event, intolerance, need for a therapeutic alternative.",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <Schedule of the study>",
        "start_page": 10,
        "end_page": 10,
        "split_index": 1
      }
    },
    {
      "text": "Row 1: Date and Duration of Row 2: Study",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <Schedule of the study>",
        "start_page": 10,
        "end_page": 10,
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Main criteria Row 2: inclusion",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <Schedule of the study>",
        "start_page": 10,
        "end_page": 10,
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key criteria Row 2: Not to be included",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <Schedule of the study>",
        "start_page": 10,
        "end_page": 10,
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Primary Judgement Criterion:Objective response rates evaluated by an independent review committee according to RECIST criteria 1.1 and defined as the proportion of patients with a complete or partial response.This response was to be confirmed by a second imaging performed at least 4 weeks later. Row 2: Key secondary judgement criteria: response time between the 1st partial or complete response and the 1st relapse or progression ( RECIST criteria 1",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <Results :>",
        "start_page": 11,
        "end_page": 11,
        "split_index": 0
      }
    },
    {
      "text": ".1) or death any cause - disease control rate: proportion of patients with a complete, partial or stable response ≥ 5 weeks - delay until response: time between the start of treatment and the 1st partial or complete response - progression-free survival, evaluated by an independent review committee: time between the start of treatment and progression or death any cause - total survival: proportion of patients with a complete, partial or stable disease ≥ 5 weeks - delay until response: time between the start of treatment and the 1st partial or complete response - progression-free survival,",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <Results :>",
        "start_page": 11,
        "end_page": 11,
        "split_index": 1
      }
    },
    {
      "text": "the start of treatment and the 1st partial or complete response - progression-free survival, evaluated by an independent review committee: time between the start of treatment and progression or death any cause - total survival: proportion of patients with a complete, partial or stable response - delay between the start of treatment and death any cause - quality of life: evaluated by the QLQLQ-C30, QLQ-LC13 and EQ-5D-5D-5L - tolerance: tolerance: size of sample: size of the sample: the sample: time: time: time of the amount of the amount of the sample: time of the amount of the amount of the",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <Results :>",
        "start_page": 11,
        "end_page": 11,
        "split_index": 2
      }
    },
    {
      "text": "time: time: time of the amount of the amount of the sample: time of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <Results :>",
        "start_page": 11,
        "end_page": 11,
        "split_index": 3
      }
    },
    {
      "text": "the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <Results :>",
        "start_page": 11,
        "end_page": 11,
        "split_index": 4
      }
    },
    {
      "text": "The analyses were then conducted all 10 evaluable responses. The study continued as long as the probability of an objective response rate exceeding 23% was ≥ 80%. The population of analysis The efficacy analyses were performed in the population known as full analysis set, corresponding to patients who received at least one dose of sotorasib + with at least one initial injury that could be assessed according to the RECIST criteria 1.1. The safety analyses were performed in the tolerance population, corresponding to patients who received at least one dose of sotorasib",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <Results :>",
        "start_page": 11,
        "end_page": 11,
        "split_index": 5
      }
    },
    {
      "text": ". Major amendments to the protocol - March 08, 2021: addition of an additional arm to 240 mg to evaluate the efficacy, safety and pharmacokinetics of this dose (available results at the end of 2022 – early 2023).",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <Results :>",
        "start_page": 11,
        "end_page": 11,
        "split_index": 6
      }
    },
    {
      "text": "Row 1: Row 2: Main Judgement Criterion",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <Results :>",
        "start_page": 11,
        "end_page": 11,
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Criteria Row 2: Judgment Row 3: Secondary Row 4: Row 5: Row 6: Row 7:",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <Results :>",
        "start_page": 11,
        "end_page": 11,
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: results analysis method",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <Results :>",
        "start_page": 11,
        "end_page": 11,
        "split_index": 0
      }
    },
    {
      "text": "Row 1:-- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <Results :>",
        "start_page": 12,
        "end_page": 12,
        "split_index": 0
      }
    },
    {
      "text": "-- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <Results :>",
        "start_page": 12,
        "end_page": 12,
        "split_index": 1
      }
    },
    {
      "text": "-- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <Results :>",
        "start_page": 12,
        "end_page": 12,
        "split_index": 2
      }
    },
    {
      "text": "Row 1:1:-- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "Table 2. Exploratory Secondary Judgement Criteria for the CodeBreak Study 100",
        "start_page": 13,
        "end_page": 13,
        "split_index": 0
      }
    },
    {
      "text": "-- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "Table 2. Exploratory Secondary Judgement Criteria for the CodeBreak Study 100",
        "start_page": 13,
        "end_page": 13,
        "split_index": 1
      }
    },
    {
      "text": "-- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "Table 2. Exploratory Secondary Judgement Criteria for the CodeBreak Study 100",
        "start_page": 13,
        "end_page": 13,
        "split_index": 2
      }
    },
    {
      "text": "Row 1: Row 2: data freeze from 01/12/2020 Row 3: N=124",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "Table 2. Exploratory Secondary Judgement Criteria for the CodeBreak Study 100",
        "start_page": 13,
        "end_page": 13,
        "split_index": 0
      }
    },
    {
      "text": "Row 1:-- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <7.3.2 Risk Management Plan (RMP) data>",
        "start_page": 14,
        "end_page": 14,
        "split_index": 0
      }
    },
    {
      "text": "-- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <7.3.2 Risk Management Plan (RMP) data>",
        "start_page": 14,
        "end_page": 14,
        "split_index": 1
      }
    },
    {
      "text": "-- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <7.3.2 Risk Management Plan (RMP) data>",
        "start_page": 14,
        "end_page": 14,
        "split_index": 2
      }
    },
    {
      "text": "Row 1: EI of all Row 2: grades",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <7.3.2 Risk Management Plan (RMP) data>",
        "start_page": 14,
        "end_page": 14,
        "split_index": 0
      }
    },
    {
      "text": "Row 1: IE Rank 2: ≥ 3",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <7.3.2 Risk Management Plan (RMP) data>",
        "start_page": 14,
        "end_page": 14,
        "split_index": 0
      }
    },
    {
      "text": "Row 1:的Name of the Study Schema,Availability of Row 2:的l-Study,How to Data,How to Use Row 3: CodeBreak 200--Phase III, randomized, open-label versus docetaxel, in adult patients with advanced KNPC with KRAS G12C mutation, previously treated,End 2022 - Early 2023--Row 4: IFCT-2012 Lung KG12--Ci--A retrospective observational study including patients treated with ATUc--Fin 2022---Row 4: IFCT-2012 Lung KG12---A retrospective observational study including patients treated with",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <08 P LAKE IN THE THERAPEUTIC STRATEGY>",
        "start_page": 18,
        "end_page": 18,
        "split_index": 0
      }
    },
    {
      "text": "4: IFCT-2012 Lung KG12---A retrospective observational study including patients treated with ATUc-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <08 P LAKE IN THE THERAPEUTIC STRATEGY>",
        "start_page": 18,
        "end_page": 18,
        "split_index": 1
      }
    },
    {
      "text": "Row 1: Assessment schedule & date of administrative validation*: 07/02/22 Review date: 20/04/2022 Adoption date: 11/05/2022 Laboratory hearing date: 15/06/2022 Row 2: Stakeholders (including patient and user associations): Yes Row 3: External expertise: Non-Row 4: Stakeholder presentations: LUMYKRAS 120 mg, film-coated tablets Box of 240 film-coated tablets (CIP: 34009 302 419 3 6) Row 5: Applicant: Amgen SAS Row 6: Stakeholder listings: Social Safety (CSS L.162-17) Communities (CSP L.5123-2) Row 7: AMM",
      "metadata": {
        "doc_id": "HTA_submission_sotosorib_FR",
        "heading": "table underheading <External expertise>",
        "start_page": 21,
        "end_page": 21,
        "split_index": 0
      }
    }
  ]
}